Geode Capital Management LLC Has $726,000 Position in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Geode Capital Management LLC grew its stake in Clearside Biomedical, Inc. (NASDAQ:CLSD) by 4.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 764,058 shares of the company’s stock after buying an additional 32,672 shares during the period. Geode Capital Management LLC owned 1.01% of Clearside Biomedical worth $726,000 as of its most recent filing with the Securities and Exchange Commission.

Clearside Biomedical Stock Down 1.7 %

CLSD stock opened at $0.85 on Friday. The stock has a 50-day simple moving average of $0.88 and a two-hundred day simple moving average of $0.97. Clearside Biomedical, Inc. has a twelve month low of $0.70 and a twelve month high of $1.65. The firm has a market capitalization of $65.69 million, a PE ratio of -1.89 and a beta of 2.04.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.27 million. On average, equities research analysts anticipate that Clearside Biomedical, Inc. will post -0.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on CLSD shares. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price target on shares of Clearside Biomedical in a report on Tuesday, April 8th. StockNews.com raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Friday, April 25th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Monday, March 31st. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Friday, March 28th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.25.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.